aTyr Receives U.S. FDA Orphan Designation for FSHD drug
San Diego-based aTyr Pharma (“aTyr”), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that Resolaris™ has been granted Orphan Drug Designation […]